• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

纳武利尤单抗联合伊匹单抗治疗转移性骨肾细胞癌：一例报告。

Nivolumab-ipilimumab in renal cell carcinoma metastatic to the bones: A case report.

机构信息

Department of Urogynecology, National Cancer Institute, Pascale Foundation, Naples, Italy.

Department of Urogynecology, National Cancer Institute Pascale Foundation , Naples, Italy.

出版信息

Acta Biomed. 2022 Jun 29;93(S1):e2022132. doi: 10.23750/abm.v93iS1.12876.

DOI:10.23750/abm.v93iS1.12876
PMID:35765962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10510992/
Abstract

In the last recent years, the introduction in the clinical setting of treatment combinations having immune checkpoint inhibitors as the backbone has dramatically improved the outcomes of patients suffering from advanced/metastatic renal cell carcinoma (RCC). Here we report the clinical course of a patient with a rapid and bulky bone recurrence of RCC after nephrectomy, experiencing long-term benefit from nivolumab-ipilimumab administered as first-line treatment.

摘要

在最近几年，以免疫检查点抑制剂为骨干的治疗组合在临床中的引入极大地改善了晚期/转移性肾细胞癌（RCC）患者的预后。在此，我们报告了一例肾细胞癌切除术后骨复发迅速且广泛的患者的临床经过，该患者接受纳武利尤单抗联合伊匹单抗作为一线治疗后长期获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a72/10510992/c6235dd47b47/ACTA-93-132-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a72/10510992/c6235dd47b47/ACTA-93-132-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a72/10510992/c6235dd47b47/ACTA-93-132-g001.jpg

相似文献

1
Nivolumab-ipilimumab in renal cell carcinoma metastatic to the bones: A case report.纳武利尤单抗联合伊匹单抗治疗转移性骨肾细胞癌：一例报告。
Acta Biomed. 2022 Jun 29;93(S1):e2022132. doi: 10.23750/abm.v93iS1.12876.
2
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼一线治疗中低危晚期肾细胞癌的成本效果分析。
Oncologist. 2019 Mar;24(3):366-371. doi: 10.1634/theoncologist.2018-0656. Epub 2019 Feb 1.
3
Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.挽救性伊匹单抗治疗肉瘤样肾细胞癌具有显著疗效。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2020-000584.
4
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼治疗晚期肾细胞癌的不良事件和成本的时间趋势。
Future Oncol. 2022 Mar;18(10):1219-1234. doi: 10.2217/fon-2021-1109. Epub 2021 Dec 23.
5
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.挽救性依匹单抗和纳武利尤单抗治疗既往免疫检查点抑制剂治疗后转移性肾细胞癌患者。
J Clin Oncol. 2020 Sep 20;38(27):3088-3094. doi: 10.1200/JCO.19.03315. Epub 2020 Jun 3.
6
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：纳武利尤单抗联合卡博替尼加入免疫检查点抑制联合治疗用于治疗初治转移性透明细胞肾细胞癌。
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
7
Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.纳武利尤单抗和伊匹单抗免疫治疗晚期肾细胞癌血液透析患者。
Curr Oncol. 2020 Aug;27(4):225-228. doi: 10.3747/co.27.6439. Epub 2020 Aug 1.
8
An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.纳武利尤单抗治疗转移性肾细胞癌的评价。
Expert Opin Biol Ther. 2018 Jun;18(6):695-705. doi: 10.1080/14712598.2018.1478962. Epub 2018 Jun 4.
9
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.依匹单抗联合纳武利尤单抗治疗肾细胞癌。
Expert Opin Biol Ther. 2018 Sep;18(9):947-957. doi: 10.1080/14712598.2018.1513485. Epub 2018 Aug 30.
10
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.尼伏单抗联合伊匹单抗治疗乳头状肾细胞癌患者的疗效一般。
Jpn J Clin Oncol. 2021 Apr 1;51(4):646-653. doi: 10.1093/jjco/hyaa229.

引用本文的文献

1
Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.IV期肾细胞癌在接受两个疗程的伊匹木单抗加纳武单抗治疗后实现病理完全缓解，尽管出现严重的免疫相关不良事件：一例报告
J Pharm Health Care Sci. 2024 May 31;10(1):26. doi: 10.1186/s40780-024-00348-8.

本文引用的文献

1
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.欧洲肿瘤内科学会（ESMO）关于免疫疗法在早期和晚期肾细胞癌中应用的临床实践指南更新
Ann Oncol. 2021 Dec;32(12):1511-1519. doi: 10.1016/j.annonc.2021.09.014. Epub 2021 Sep 28.
2
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.多机构回顾性分析联合应用依匹单抗和纳武单抗治疗骨转移肾细胞癌患者。
Target Oncol. 2021 Sep;16(5):633-642. doi: 10.1007/s11523-021-00832-3. Epub 2021 Aug 11.
3
Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
新靶点治疗和消融治疗选择背景下骨转移放疗的进展：批判性评价。
Radiother Oncol. 2021 Oct;163:55-67. doi: 10.1016/j.radonc.2021.07.022. Epub 2021 Jul 29.
4
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的黑色素瘤和肾细胞癌患者的 COVID-19 的临床和免疫学意义。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002835.
5
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
6
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
7
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.派姆单抗联合阿昔替尼对比舒尼替尼作为晚期肾细胞癌的一线治疗（KEYNOTE-426）：一项随机、开放标签、III 期试验的延长随访。
Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23.
8
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.纳武利尤单抗联合伊匹木单抗与舒尼替尼一线治疗晚期肾细胞癌：III期CheckMate 214试验的4年延长随访
ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079.
9
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.接受纳武单抗治疗的晚期黑色素瘤、肾细胞癌或非小细胞肺癌患者的五年生存率及相关因素
JAMA Oncol. 2019 Oct 1;5(10):1411-1420. doi: 10.1001/jamaoncol.2019.2187.
10
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.